No black box warning on record for Segluromet

As of the latest FDA labeling reviewed, Segluromet (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Segluromet medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Lactic Acidosis: See boxed warning . ( 5.1 ) Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue SEGLUROMET if ketoacidosis is suspected. Monitor patients for resolution of

No black box warning on record for Segluromet

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Lactic Acidosis: See boxed warning . ( 5.1 ) Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue SEGLUROMET if ketoacidosis is suspected. Monitor patients for resolution of

Segluromet Black Box Warning

No black box warning on record for Segluromet

Other warnings & precautions

Segluromet Black Box Warning

No black box warning on record for Segluromet

Other warnings & precautions